Clinical trials are pivotal in cardiac drug development, yet they often fail due to inadequate efficacy and unexpected safety issues, leading to significant financial losses. Using in-silico trials to replace a part of physical clinical trials, e.g., leveraging advanced generative models to generate drug-influenced electrocardiograms (ECGs), seems an effective method to reduce financial risk and potential harm to trial participants. While existing generative models have demonstrated progress in ECG generation, they fall short in modeling drug reactions due to limited fidelity and inability to capture individualized drug response patterns. In this paper, we propose a Drug-Aware Diffusion Model (DADM), which could simulate individualized drug reactions while ensuring fidelity. To ensure fidelity, we construct a set of ordinary differential equations to provide external physical knowledge (EPK) of the realistic ECG morphology. The EPK is used to adaptively constrain the morphology of the generated ECGs through a dynamic cross-attention (DCA) mechanism. Furthermore, we propose an extension of ControlNet to incorporate demographic and drug data, simulating individual drug reactions. We compare DADM with the other eight state-of-the-art ECG generative models on two real-world databases covering 8 types of drug regimens. The results demonstrate that DADM can more accurately simulate drug-induced changes in ECGs, improving the accuracy by at least 5.79% and recall by 8%.

Adverse Drug Reactions (ADRs) from psychiatric medications are the leading cause of hospitalizations among mental health patients. With healthcare systems and online communities facing limitations in resolving ADR-related issues, Large Language Models (LLMs) have the potential to fill this gap. Despite the increasing capabilities of LLMs, past research has not explored their capabilities in detecting ADRs related to psychiatric medications or in providing effective harm reduction strategies. To address this, we introduce the Psych-ADR benchmark and the Adverse Drug Reaction Response Assessment (ADRA) framework to systematically evaluate LLM performance in detecting ADR expressions and delivering expert-aligned mitigation strategies. Our analyses show that LLMs struggle with understanding the nuances of ADRs and differentiating between types of ADRs. While LLMs align with experts in terms of expressed emotions and tone of the text, their responses are more complex, harder to read, and only 70.86% aligned with expert strategies. Furthermore, they provide less actionable advice by a margin of 12.32% on average. Our work provides a comprehensive benchmark and evaluation framework for assessing LLMs in strategy-driven tasks within high-risk domains.

The mining of adverse drug events (ADEs) is pivotal in pharmacovigilance, enhancing patient safety by identifying potential risks associated with medications, facilitating early detection of adverse events, and guiding regulatory decision-making. Traditional ADE detection methods are reliable but slow, not easily adaptable to large-scale operations, and offer limited information. With the exponential increase in data sources like social media content, biomedical literature, and Electronic Medical Records (EMR), extracting relevant ADE-related information from these unstructured texts is imperative. Previous ADE mining studies have focused on text-based methodologies, overlooking visual cues, limiting contextual comprehension, and hindering accurate interpretation. To address this gap, we present a MultiModal Adverse Drug Event (MMADE) detection dataset, merging ADE-related textual information with visual aids. Additionally, we introduce a framework that leverages the capabilities of LLMs and VLMs for ADE detection by generating detailed descriptions of medical images depicting ADEs, aiding healthcare professionals in visually identifying adverse events. Using our MMADE dataset, we showcase the significance of integrating visual cues from images to enhance overall performance. This approach holds promise for patient safety, ADE awareness, and healthcare accessibility, paving the way for further exploration in personalized healthcare.

Adverse drug reactions considerably impact patient outcomes and healthcare costs in cancer therapy. Using artificial intelligence to predict adverse drug reactions in real time could revolutionize oncology treatment. This study aims to assess the performance of artificial intelligence models in predicting adverse drug reactions in patients with cancer. This is the first systematic review and meta-analysis. Scopus, PubMed, IEEE Xplore, and ACM Digital Library databases were searched for studies in English, French, and Arabic from January 1, 2018, to August 20, 2023. The inclusion criteria were: (1) peer-reviewed research articles; (2) use of artificial intelligence algorithms (machine learning, deep learning, knowledge graphs); (3) study aimed to predict adverse drug reactions (cardiotoxicity, neutropenia, nephrotoxicity, hepatotoxicity); (4) study was on cancer patients. The data were extracted and evaluated by three reviewers for study quality. Of the 332 screened articles, 17 studies (5%) involving 93,248 oncology patients from 17 countries were included in the systematic review, of which ten studies synthesized the meta-analysis. A random-effects model was created to pool the sensitivity, specificity, and AUC of the included studies. The pooled results were 0.82 (95% CI:0.69, 0.9), 0.84 (95% CI:0.75, 0.9), and 0.83 (95% CI:0.77, 0.87) for sensitivity, specificity, and AUC, respectively, of ADR predictive models. Biomarkers proved their effectiveness in predicting ADRs, yet they were adopted by only half of the reviewed studies. The use of AI in cancer treatment shows great potential, with models demonstrating high specificity and sensitivity in predicting ADRs. However, standardized research and multicenter studies are needed to improve the quality of evidence. AI can enhance cancer patient care by bridging the gap between data-driven insights and clinical expertise.

Adverse drug reaction (ADR) prediction plays a crucial role in both health care and drug discovery for reducing patient mortality and enhancing drug safety. Recently, many studies have been devoted to effectively predict the drug-ADRs incidence rates. However, these methods either did not effectively utilize non-clinical data, i.e., physical, chemical, and biological information about the drug, or did little to establish a link between content-based and pure collaborative filtering during the training phase. In this paper, we first formulate the prediction of multi-label ADRs as a drug-ADR collaborative filtering problem, and to the best of our knowledge, this is the first work to provide extensive benchmark results of previous collaborative filtering methods on two large publicly available clinical datasets. Then, by exploiting the easy accessible drug characteristics from non-clinical data, we propose ADRNet, a generalized collaborative filtering framework combining clinical and non-clinical data for drug-ADR prediction. Specifically, ADRNet has a shallow collaborative filtering module and a deep drug representation module, which can exploit the high-dimensional drug descriptors to further guide the learning of low-dimensional ADR latent embeddings, which incorporates both the benefits of collaborative filtering and representation learning. Extensive experiments are conducted on two publicly available real-world drug-ADR clinical datasets and two non-clinical datasets to demonstrate the accuracy and efficiency of the proposed ADRNet. The code is available at https://github.com/haoxuanli-pku/ADRnet.

Healthcare analytics company MDI Health scored $20 million in Series A funding, bringing the company's total funding to $26 million. Intel Capital led the round with participation from Maverick Ventures Israel alongside existing investors Fresh.Fund, Arc Impact, Hanaco Ventures, Jumpspeed Ventures, former Optum senior vice president Richard Montwill, Welltech Ventures and Basad Ventures. Yoni Greifman, Intel Capital's investment director, will join MDI's board of directors. Israel-based MDI offers an AI-enabled tool that provides medication risk analysis based on a patient's medical records with the aim of preventing adverse drug reactions. The funds will help the company scale its U.S. and Israeli research and development teams.

In this work, we present the first corpus for German Adverse Drug Reaction (ADR) detection in patient-generated content. The data consists of 4,169 binary annotated documents from a German patient forum, where users talk about health issues and get advice from medical doctors. As is common in social media data in this domain, the class labels of the corpus are very imbalanced. This and a high topic imbalance make it a very challenging dataset, since often, the same symptom can have several causes and is not always related to a medication intake. We aim to encourage further multi-lingual efforts in the domain of ADR detection and provide preliminary experiments for binary classification using different methods of zero- and few-shot learning based on a multi-lingual model. When fine-tuning XLM-RoBERTa first on English patient forum data and then on the new German data, we achieve an F1-score of 37.52 for the positive class. We make the dataset and models publicly available for the community.

For generations healthcare has been episodic – someone gets sick or breaks a bone, they see a doctor, and then they might not see another one until the next time they get sick or injured. Now, as emerging technologies such as artificial intelligence open up new possibilities for the healthcare industry in the Fourth Industrial Revolution, policymakers and practitioners are developing new ways to deliver continuous healthcare for better outcomes. Consumers already expect access to healthcare providers to be as smart and easy as online banking, retrieving boarding passes and making restaurant reservations, according to Kaiser Permanente CEO Bernard J Tyson. Nearly three-quarters of Americans with health insurance (72%), for example, say it's important that their health insurance provider uses modern communication tools, such as instant message and two-way video. Innovative healthcare organizations such as Kaiser Permanente are listening.

Adverse drug reaction (ADR) is a major burden for patients and healthcare industry. It usually causes preventable hospitalizations and deaths, while associated with a huge amount of cost. Traditional preclinical in vitro safety profiling and clinical safety trials are restricted in terms of small scale, long duration, huge financial costs and limited statistical signifi- cance. The availability of large amounts of drug and ADR data potentially allows ADR predictions during the drugs’ early preclinical stage with data analytics methods to inform more targeted clinical safety tests. Despite their initial success, existing methods have trade-offs among interpretability, predictive power and efficiency. This urges us to explore methods that could have all these strengths and provide practical solutions for real world ADR predictions. We cast the ADR-drug relation structure into a three-layer hierarchical Bayesian model. We interpret each ADR as a symbolic word and apply latent Dirichlet allocation (LDA) to learn topics that may represent certain biochemical mechanism that relates ADRs with drug structures. Based on LDA, we designed an equivalent regularization term to incorporate the hierarchical ADR domain knowledge. Finally, we developed a mixed input model leveraging a fast collapsed Gibbs sampling method that the complexity of each iteration of Gibbs sampling proportional only to the number of positive ADRs. Experiments on real world data show our models achieved higher prediction accuracy and shorter running time than the state-of-the-art alternatives.